hai M-segment DNA vaccines Conferences | Meetings | Events | Symposiums | ConferenceSeries

International Conferences

Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

 

Recommended Conferences for M-segment DNA vaccines

M-segment DNA vaccines


As per available reports about 17 open access articles, 28 conferences, 3 national symposiums are presently dedicated exclusively to MVA and about 13 speakers gave presentations on MVA.

The Modified Vaccinia Ankara (MVA) is an attenuated vaccine of a poxvirus. It was licensed and used as a poxvirus vaccine in Bavaria and is a vector for vaccination against non-poxvirus diseases. Vaccinia viruses re-engineered to express foreign genes are vectors for production of recombinant proteins, the most common being a vaccine delivery system for antigens. Concerns about the safety of the vaccinia virus have been addressed by the development of vectors based on attenuated vaccinia viruses. One of them, the Modified Vaccinia Ankara (MVA') virus, is a highly attenuated strain of vaccinia virus that was developed towards the end of the campaign for the eradication of smallpox by Anton Mayr in Germany. Produced by more than 500 passages of vaccinia virus in chicken cells (chicken embryo fibroblast, MVA has lost about 10% of the vaccinia genome and with it the ability to replicate efficiently in primate cells. A recombinant MVA-based vector for vaccination with different fluorescent reporter genes was developed by Antonio Siccardi, which indicate the progress of genetic recombination with the transgene of an antigen

OMICS International 1000+ Global Events Every Year across USA, Europe & Asia with support from 1000 more scientific societies  and Publishes 700+ Open access journals Open access journals which contains over 100000 eminent personalities, reputed scientists as editorial board and organizing committee members. The conference series website will provide you list and details about the conference organize worldwide.

MVA is widely considered as the vaccinia virus strain of choice for clinical investigation because of its high safety profile. MVA has been administered to numerous animal species including monkeys, mice, swine, sheep, cattle, horses, and elephants, with no local or systemic adverse effects. Over 120,000 humans have been safely and successfully vaccinated against smallpox with MVA by intradermal, subcutaneous, or intramuscular injections. Currently, the use of MVA as a recombinant HIV vaccine (MVA-B) is being tested in approximately 300 volunteers in several Phase I studies conducted by the International AIDS Vaccine Initiative. Studies in mice and nonhuman primates have further demonstrated the safety of MVA under conditions of immune suppression. Compared to replicating vaccinia viruses, MVA provides similar or higher levels of recombinant gene expression even in non-permissive cells. Recently, vaccination with smallpox vaccine (a vaccinia virus related to MVA) has been shown, on rare occasions, to cause heart problems in people who received it: heart inflammation (myocarditis), inflammation of the membrane covering the heart (pericarditis), and a combination of these two problems (myopericarditis). A few cases of cardiac chest pain (angina) and heart attack have also been reported following smallpox vaccination. It is not known at this time if smallpox vaccination causes angina or heart attacks. MVA is an attenuated vaccinia virus and does not replicate in the human body as efficiently as vaccinia. However. Whether or not MVA can induce the same side effects as vaccinia is not known at this time.

Relevant Conferences:

  1. 7th Vaccines & Vaccination Conference, September 28-30, 2015 Dubai, UAE
  2. 9th Vaccines & Vaccination Conference,                                                           November 30-December 02, 2015 San Francisco, USA
  3. 10th Vaccines & Vaccination Conference, June 16-18, 2016 Rome, Italy
  4. 13th Vaccines & Vaccination Conference,                                                         November 10-12, 2016 Melbourne, Australia
  5. 2nd Applied Microbiology Conference,                                                             October 31-November 02, 2016 Istanbul, Turkey
  6. 6th Cell & Stem Cells Research Conference,                                                      February 29-March 02, 2016 Philadelphia, USA
  7. 2nd Antibiotics Conference October 03-05, 2016 London, UK
  8. 5th Cancer Therapy Conference, September 28-30, 2015 Atlanta, Georgia, USA
  9. Beneficial Microbes: Food, Pharma, Aqua & Beverages Industry Conference, September 23-25, 2016 Phoenix, USA
  10. 4th Bacteriology and Infectious Diseases Conference,                                        May 16-18, 2016 San Antonio, USA
  11. Allergy Conference, March 29-30, 2016 Valencia, Spain
  12. 4th Immunology Conference, September 28-30, 2015 Houston, Texas, USA
  13. 2nd Infectious Diseases Conference, August 25-27, 2016 Philadelphia, USA
  14. 2nd Influenza Conference, September 12-14, 2016 Berlin, Germany
  15. Infection Prevention and Control Conference, Aug 1-2, 2016 Frankfurt, Germany
  16. 2nd Innate Immunity Conference, July 21-22, 2016 Berlin, Germany
  17. 2nd Parasitology Conference, August 01-03, 2016 Manchester, UK
  18. 2nd Antibodies Conference, July 14-15, 2016 Philadelphia, USA
  19. 2nd Neuroimmunology & Therapeutics Conference,                                        March 31-April 02, 2016 Atlanta, USA
  20. Influenza Vaccines for the World, 6-9 October 2015 Sao Rafael Atlantic Hotel, Albufeira, Algarve, Portugal
  21. The 2015 Vaccine Summit, 13th - 15th October 2015 Cineworld: The O2, Peninsula Square, London
  22. Conference on 3Rs Alternatives and Consistency Testing in Vaccine Lot Release Testing, 16 -18 September 2015 Hotel Zuiderduin, The Netherlands
  23. Meningitis and Septicaemia in Children and Adults, 4th - 5th November 2015 Royal Society of Medicine, London, United Kingdom
  24. Conference on 3Rs Alternatives and Consistency Testing in Vaccine Lot Release Testing, 16 -18 September 2015 Hotel Zuiderduin, The Netherlands
  25. Meningitis and Septicaemia in Children and Adults, 4th - 5th November 2015 Royal Society of Medicine, London, United Kingdom

Relevant Societies:

  1. Infectious Diseases Society of America
  2. International Society for Infectious Diseases
  3. Southern African HIV Clinicians Society
  4. Australian Federation Aids Organizations
  5. ANTIAIDS Foundation
  6. Apparel Lesotho Alliance to fight AIDS
  7. AIDS Action Committee of Massachusetts
  8. AIDS Foundation Houston
  9. Antimicrobial resistance - Royal Society
  10. American Society for Microbiology
  11. Red Cross Red Crescent Societies (IFRC)
  12. Ecuadorian Society of Medical Technologists Laboratory (SOTEMELAB)
  13. European Society of Clinical Microbiology and Infectious Diseases
  14. Médecins Sans Frontières
  15. American Chemical Society
  16. American Federation for Medical Research

Relevant Companies:

  1.  National Medicines Institute
  2.  Crown Bioscience, Inc.
  3.  Metabolon, Inc.
  4.  Redx Pharma
  5. Boston Biomedical
  6.  Ustar Biotechnologies (Hangzhou) Ltd.
  7. Zakłady Chemiczne Permedia S.A.
  8.  AstraZeneca
  9.  Astellas
  10.  Bayer's Pharma
  11.  Cipla
  12.  Dr. Reddy’s Laboratories Ltd.
  13.  GlaxoSmithKline plc.
  14.  Gilead
  15.  Merck & Co.
  16.  Natco Pharma
  17.  Novartis
  18.  Novo Nordisk
  19. Pfizer
  20.  Roche
  21.  Sunpharma
  22.  Sanofi
  23.  Vaxgen

This page will be updated regularly.

This page was last updated on November 5, 2024

Conference Series Destinations